Accelerate Clinical Trials With AI and Real-Time Data Collaboration
Discover a unified clinical data review and collaboration solution that optimizes the integration and review of complex, ever-changing clinical data.
Regarding “the organization” that needs to inform the FDA of the intended use of electronic signatures, in a CRO/Sponsor relationship, who is responsible: the CRO or the Study Sponsor?
This question is referring to Subpart C – Electronic Signatures, Section 11.100 General Requirements, letter (c): Persons using electronic signatures shall, prior to or at the time of such use, certify to the agency that the electronic signatures in their system, used on or after August 20, 1997, are intended to be the legally binding equivalent of traditional handwritten signatures.
As we understand it, the organization that is ultimately responsible for the electronic records that will be signed electronically should be the one to notify the FDA. In the CRO/Sponsor situation, that would most likely be the Sponsor.